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TISSUE-ENGINEERED VASCULAR GRAFTS ALLOW NEOVESSEL FORMATION BY 
RECRUITING ADJACENT VASCULAR TISSUE. 
Adam Shoffner, Narutoshi Hibino, Gustavo Villalona, Nicholas Pietris, Daniel R. Duncan, 
Jason D. Roh, Tai Yi, Lawrence W. Dobrucki, Dane Mejias, Rajendra Sawh-Martinez, 
Jamie K. Harrington, Albert Sinusas, Diane S. Krause, Themis Kyriakides, W. Mark 
Saltzman, Jordan S. Pober, Toshiharu Shin’oka, and Christopher K. Breuer. 
Interdepartmental Program in Vascular Biology and Therapeutics, Yale University, 
School of Medicine, New Haven, Connecticut, USA. 
 
Hypothesis: Tissue Engineered Vascular Grafts (TEVGs) constructed by seeding cells 
autologous bone marrow-derived mononuclear cells onto dissolvable scaffolding aid in the 
recruitment of cells from either the host’s bone marrow or neighboring vasculature to 
form the graft neotissue. 
Methods: RT-PCR was performed on explanted grafts to detect presence of seeded cells. 
FISH for Y chromosome was performed on female mice with male bone marrow transplant 
along with female mice with implanted male-composite TEVG.  
Results: The seeded cells on implanted TEVGs decrease precipitously from 4.37% to 
0.02% from 6hr to 14 days. At 6 months post implantation composite graft TEVGs 
displayed a high percentage of Y chromosome-positive cells adjacent to male inferior vena 
cava tissue. Explanted grafts from female mice following male bone marrow transplant 
revealed no neotissue positive for Y chromosome.  
Discussion: TEVGs derive their neotissue from adjacent vasculature following 
implantation that is mechanistically aided by the presence of seeded bone marrow-
derived mononuclear cells.  
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Introduction:  
 
In North America, Congenital Heart Defects (CHDs) continue to be the 
leading cause of death within the infant population (1). Occurring in 
approximately 0.8% of live births some CHDs are clinically non-significant, 
however others are clearly associated with significant morbidity and 
mortality (2). Many less severe CHDs are readily controllable with 
observation and medical therapy. However, more complicated defects such 
as tetrology of Fallot and single ventricle defects require surgical methods 
for the establishment of physiologic blood flow (3).   
 
The atria, ventricles, valves, and great vessels can all be anomalous in 
CHDs (4). Occasionally a primary repair of the defect is possible. However, 
often the use of a prosthetic graft is necessary for anatomical continuity in 
cases of greater complexity such as in single ventricle anomalies. These 
single ventricle anomalies include pulmonary or tricuspid atresia along 
with hypoplastic left heart syndromes (4).  Together, these represent one 
of the largest groups of CHDs that can result in life-threatening disease as 
they allow for the mixing of oxygenated and deoxygenated blood and 
resultant chronic hypoxia and cyanosis. Additionally, the mixing of blood 
can cause volume overload leading to heart failure. Left untreated, 
mortality during the first year of life is 70% (5).  
Since its introduction in 1971 the Fontan procedure (6) has been the 
treatment of choice for single ventricle anomalies. The ultimate goal of the 
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procedure is to separate the pulmonary from systemic circulation (7,8). 
This involves the diversion of blood into the pulmonary artery directly 
from the inferior vena cava (IVC) and is known as the modified Fontan 
operation with extra cardiac total cavopulmonary connection (EC TCPC) 
(7,8).  
 
Traditionally the Fontan procedure has required a prosthetic vascular 
conduit to direct the blood from either the IVC or right atrium (6). Other 
CHDs requiring prosthesis include tetrology of Fallot and coarctation of the 
aorta. Tetrology of Fallot may require a vascular conduit to establish flow 
from the right heart to the pulmonary circuit in a similar manor to the 
Fontan procedure (4,9,10,11). Patients may also require a prosthetic valve 
to repair a diseased valve (12). Coarctation of the aorta may require a 
prosthetic vascular conduit connecting the aorta, distal to the coarctation, 
to the left ventricle.  Additionally, large atrial or ventricular septal defects 
may require prosthetic patches for repair (4).  
 
These procedures and the use of prosthetic grafts have led to rapid 
development and improvements in the field of pediatric cardiothoracic 
surgery over the last century. However, despite these improvements there 
continues to exist significant morbidity and mortality associated with the 
repair of CHDs (13,14). There are several reasons for this continuation. 
One reason being that advancements in the field have allowed surgeons to 
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attempt repairs of the most complex defects (4). A second reason is that 
the use of prostheses is not without their pitfalls. Synthetic vascular grafts 
currently in use, such as polytetrafluoroethylene, lack the ability to grow. 
Additionally they have numerous problems associated with the 
development of thrombosis, ectopic calcification, and increased infection 
susceptibility (15,16). These problems with synthetic prostheses have 
contributed to the continued morbidity and mortality associated with the 
repair of CHDs. The lack of prosthesis growth potential often forces the 
pediatric patient to endure multiple procedures to upsize the graft as the 
patient grows. This exposes the patient to the morbidity and mortality 
associated with having to undergo multiple surgeries (14). Two strategies 
have been used in an effort to address the lack of growth potential. The 
first strategy is to delay surgery until the patient has reached a suitable 
size allowing for the implantation of an adult-sized graft (17). A second 
option is the implantation of an oversized graft. There are problems 
associated with both options. The delay of surgery can result in both 
volume overload and chronic hypoxia. Chronic hypoxia has been 
associated with developmental delays and failure to thrive (18). Volume 
overload may cause cardiac failure. The option to use an oversized graft 
often results in turbulent blood flow which increases the risk of 
thromboembolic complications which are a leading cause of graft failure 
and postoperative morbidity and mortality (17).  
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Due to these limitations associated with prosthetic grafts, alternatives that 
address these issues could greatly reduce the morbidity and mortality that 
is currently associated with surgical repair of CHDs. Tissue-engineered 
vascular grafts (TEVGs) have recently been shown to provide an attractive 
alternative to prosthetic grafts (19-22). A number of approaches, 
including in vivo blood vessel engineering, the use of explanted native 
vessels as a living scaffold, using biodegradable polymeric scaffolds onto 
which various cells can be seeded prior to implantation, and scaffold-free 
approaches have all been investigated (23-25). Unfortunately, none of 
these have resulted in the creation of an ideal TEVG.  
 
TEVGs constructed from the seeding of a biodegradable polymeric 
scaffolding with cells has revealed promising results. Shinoka et al. 
described the first implantations of TEVGs into 25 pediatric patients for 
the repair of single ventricle defects in 2001 (26-28). The conduits were 
used to create EC TCPC during repair of right ventricle outflow defects or 
single ventricle anatomy (29,30). A poly-L-lactide (PLLA) with a 
copolymer of lactide and ε-caprolactone (P(CL/LA)) was seeded with 
autologous bone marrow mononuclear cells (BM-MNC) harvested on the 
day of the surgery. Prior to implantation, seeded conduits were maintained 
in culture media for 2-4 h (29). All of the patients that received a TEVG 
were evaluated by echocardiography, angiography, computerized 
tomography, and/or magnetic resonance imaging. Long-term follow-up has 
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revealed graft stenosis in 16% of patients, however this was typically 
asymptomatic and all have been treated successfully with stenting and 
angioplasty.  
 
Based on these data the use of TEVGs as EC TCPC for the repair of single 
ventricle defects is very promising as it has been shown to be both safe and 
effective. However, despite these encouraging results, the mechanisms 
that underlie the process of graft formation and failure continue to remain 
poorly understood. It has been hypothesized that the formation of 
neotissue forms from cells that have been seeded onto the biodegradable 
scaffold (31). Within this hypothesis these seeded cells are believed to 
divide and differentiate into endothelial cells as the scaffold degrades, 
resulting ultimately in a purely biological structure without any synthetic 
components that has the ability to repair, remodel, and grow in concert 
with the patient.  
 
In an effort to better understand these underlying processes we 
miniaturized the procedure to allow for a TEVG to be implanted as an IVC 
interposition graft in a mouse recipient. Scaffolds were created from the 
same synthetic materials and design as used clinically to allow for the 
retention of structural, mechanical, and degradation properties.   
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Statement:  
 
It was hypothesized that, contrary to the accepted paradigm, autologous 
bone marrow-derived mononuclear cells (BMMCs) when seeded onto a 
biodegradable scaffold and implanted into mice as tissue engineered 
vascular grafts (TEVGs) that seeded cells do not differentiate and divide to 
become the neotissue. Furthermore it was hypothesized that the source of 
the cells that ultimate become neotissue was either the vasculature 
adjacent to the implanted TEVG or cells arising in the host’s own bone 
marrow.  
 
Methods: 
 
In the following methods I performed the experiments involved with all 
qRT-PCR. This includes the isolation and purification of DNA from mice, 
the generation of a reproducible standard curve allowing for the 
measurement of mouse genomes/µL, design of the primers and probes, and 
the qRT-PCR performed on all explanted mouse TEVGs. All other 
experiments were performed by other members of the laboratory.  
 
o Isolation & purification of DNA from GFP + Mice 
 
With the ultimate goal of creating a quantitative Polymerase Chain 
Reaction (qPCR) experiment that would allow for the tracking of Green 
Fluorescent Protein (GFP)-positive mouse cells in explanted Tissue 
Engineered Vascular Grafts (TEVGs), purified whole mouse genomic DNA 
was initially needed from both GFP-positive and GFP-negative mice. This 
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DNA was needed for the creation of both positive and negative controls to 
test and optimize the primers necessary for the reaction. Additionally, the 
DNA was required for the creation of a DNA standard curve that would 
ultimately allow for the quantification of GFP-positive genomes in the 
explanted mouse samples.  After concentrating the cells, approximately 5 
x 106 GFP-positive Bone Marrow-Derived Mononuclear Cells (BM-MNCs 
obtained from C57BL/6 GFP-positive mice were resuspended in 200 uL 
lysis buffer (Qiagen, Valenica, CA, USA) and incubated overnight at 56° C 
in Proteinase K (12 mAu/reaction) to aid in the DNA extraction. Following 
tissue digestion, the whole genomic DNA was then isolated using DNeasy 
blood and tissue kit (Qiagen) following the manufacturer’s instructions.  
DNA was eluted from the column with 200 uL Buffer AE (Qiagen) and 
stored at + 4° C.  For use as a negative control in downstream experiments, 
DNA was isolated from (non-GFP + mice) in a manor identical to that 
previously described. The DNA concentrations were then determined using 
the NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA) per 
manufacture’s instruction.  
 
o Standard Curve Generation 
 
The creation of the standard curve is one of the most important aspects of 
this experiment. The standard curve allows for the determination of the 
amount of DNA present in unknown samples. Using the molecular weight 
of the mouse genome at 4 x 1012 grams/mol (32) the DNA concentration 
with the units genomes/µL was determined. A working dilution of 20,000 
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genomes/µL was created. This allowed for 10-fold serial dilutions to be 
performed by placing 20 µL of DNA into 180 µL ddH2O to a concentration 
of .2 genome/µL. These dilutions were subsequently used as qPCR 
standards by adding 5 µL of each concentration to each reaction resulting 
in a standard curve from 1x105 genomes to 1 genome. The standard curve 
was run in triplicate in all experiments.  
 
o Design of primers & probe 
 
The gene of interest in this experiment is the GFP gene. Since its discovery 
in the 1960s (33) the GFP gene has been modified numerous times 
creating multiple different gene sequences. The most popular of these is 
the enhanced-GFP (EGFP) mutant (34) that allows for use of the gene in 
mammalian cells.  In an effort to ensure that the primers designed for this 
experiment would be useful across numerous GFP strains the most 
common three GFP strains were compared.  Using guidelines to ensure a G-
C content of approximately 20-80%, avoidance of consecutive identical 
nucleotides, avoidance of a guanine on the 5’ end, and an ideal melting 
temperature of 68° primers were designed that adhered to these rules and 
amplified a 93 base pair region that was completely conserved between the 
three GFP strains. (Applied Biosystems) The following primers and probe 
were chosen: forward, 5’ –ACCACATGAAGCAGCACGACTTCT- 3’; reverse, 5’ 
–TGTAGTTGCCGTCGTCCTTGAAGA- 3’; probe, 5’-
AAGGCTACGTCCAGGAGCGCACCAT- 3’.  The primers were synthesized by 
W.M. Keck Oligonucleotide Synthesis Facility at Yale University. The 
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primers were reconstituted in H2O, the amount of which was determined 
by multiplying the total nanomoles of primer by four with the product 
being the volume of H2O added. Theoretically this should yield a final 
primer concentration of 250 uM. The concentrations of the reconstituted 
primers were verified by recording the A260 of the primers using the 
spectrophotometer (Nanodrop). By calculating the sum of the extinction 
coefficients for each primer by using the primer gene sequences the 
following equation was used to most accurately determine the primer 
concentrations:  
A260 = Sum of Extinction Coefficient x Path Length x Concentration/100 
 
As primers are not double stranded and are considerably shorter than 
whole genomic DNA this method of determining concentration has greater 
accuracy than methods previously described. 1:10 working dilutions were 
made in H2O and stored at + 4° C for future use.  
 
The TaqMan (Applied Biosystems) probe was labeled at the 5’ end with 6-
carboxyfluorescein (FAM). The 3’ end was labeled with TAMRA quencher. 
TaqMan probes allow for quantification of specific amplification products. 
A fluorescent signal will be detected by the RT-PCR machine only following 
the release of the 3’ quencher by the DNA polymerase which occurs only 
during amplification of specific DNA sequences.  
 
A SYBR Green (Applied Biosystems, Foster City, CA, USA) qPCR reaction 
was performed to test the specificity of the primers. Compared to TaqMan 
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probes, real-time PCR with SYBR Green yields similar data. However, 
SYBR Green emits a fluorescent signal upon DNA intercalation. This is less 
specific than TaqMan as any double stranded DNA, regardless of source, is 
capable of SYBR Green intercalation resulting in a false positive signal.  
The reaction was carried out with a final volume of 25 µL containing 12.5 
µL SYBR Green Master Mix (Applied Biosystems), 0.41 µL (15.3 µM) of 
forward and 0.496 µL (12.6 µM) reverse primers, 5 µL template DNA, and 
6.59 µL ddH2O. The DNA template consisted of a standard curve as 
previously described containing GFP- positive mouse DNA.  A negative 
control consisting of an identical standard curve created using GFP- 
negative mouse DNA was run. Additionally, negative controls that 
contained all reagents minus template DNA were run. Each SYBR Green 
qPCR reaction consisted of the following steps: 10 minutes at 95°C to 
activate the polymerase, and 40 cycles of 15 seconds denaturing at 95°C 
and 1 minute at 60°C of extension and annealing. Following the completion 
of 40 cycles a melting curve was performed to determine purity of the 
amplicons. Data were collected at the end of each elongation step and 
analyzed with iCycler iQ Real Time Detection System Software (Bio-Rad, 
Hercules, CA, USA).  To further ensure amplicon specificity products from 
SYBR Green PCR were run on a 4% NuSieve 3:1 Plus Agarose Gel (Lonza 
Inc., Walkersville, MD, USA) in 1x TAE buffer. 8 µL of PCR product 
decreasing to 3 µL in 1 µL increments over successive wells were run with 
2 µL loading buffer (Invitrogen, Grand Island, NY, USA). ddH2O was used to 
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bring total volume to 10 µL/lane.  Gel was imaged using Gel Doc XR+ 
System (Bio-Rad). 
 
In an effort to ensure that the TaqMan PCR was as sensitive and specific as 
possible when applied to the future experiments a number of optimization 
experiments were performed. The optimal primer concentration was 
investigated by performing PCR reactions with primer concentrations of 
125 nM, 250 nM, 500 nM and 1000 nM. PCR was carried out with a final 
volume of 20 µL containing 10 µL of TaqMan Universal PCR Master Mix-
UDG (Applied Biosystems), 0.5 µL (10.0 µM) of the TaqMan probe, and 5 
µL of DNA. Varying amounts of both forward and reverse primers were 
added as described to reach the desired concentrations and ddH2O was 
added to bring the final volume of each reaction to 20 µL. The template 
DNA used for each reaction was the standard curve in triplicate for each 
primer concentration as described above. Each qPCR reaction consisted of 
the following steps: 2 minutes UNG incubation at 50°C to remove possible 
amplicon contamination, followed by 10 minutes at 95°C to activate the 
polymerase. 40 cycles of 15 seconds denaturing at 95°C and 1 minute at 
60°C for extention and annealing were performed. Data were collected at 
the end of each elongation step and analyzed with iCycler iQ Real-Time PCR 
Detection System (Bio-Rad). 
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Following determination of the optimal primer concentration the 
experiment was repeated as described above to investigate the impact on 
the sensitivity and specificity of the qRT-PCR reaction that the presence of 
a large amount of background non-specific mouse DNA would have. The 
reasoning behind performing this additional experiment lay in an 
understanding that the vast majority of DNA present in the experimental 
mouse samples would be non-GFP DNA. Because of this, it was imperative 
to know the effects on sensitivity that this DNA could potentially play in 
our experiments. The qRT-PCR was performed as described previously 
however, 1x105 genomes of GFP-negative mouse DNA was added to each 
reaction.  
 
Following optimization experiments all TaqMan PCR was carried out with 
a final volume of 20 µL containing 10 µL of TaqMan Universal PCR Master 
Mix-UDG (Applied Biosystems), 0.33 µL (15.3 µM) of forward and 0.396 
µL (12.6 µM) reverse primer, 0.5 µL (10.0 µM) of the TaqMan probe, up to 
5 µL of DNA and 3.774 µL of ddH2O. 6000 mouse genomes per sample were 
added to each reaction. For consistency, ddH2O was added to each reaction 
to bring the final DNA template volume to 5 µL.  
 
Negative controls that contained all reagents except the target DNA, along 
with 10-fold serial dilutions of positive control DNA were included in each 
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run. Additionally, explanted inferior vena cava from a GFP- negative 
mouse was used as a negative control.  
 
o Scaffold Fabrication 
 
The scaffolds for the TEVGs were constructed from a nonwoven 
polyglycolic acid (PGA) mesh (Concordia Fibers, Coventry, RI, USA) and a 
copolymer sealant solution of poly-L-lactide and ε-caprolactone [P(CL/LA)] 
using the dual cylinder chamber molding system as previously described 
(35). 
o BMMC isolation and TEVG assembly 
 
Bone marrow was collected from the femurs of syngeneic CB57BL/6 mice 
(Jackson Laboratories, Bar Harbor, ME, USA). Following purification of the 
mononuclear cell component using Histopaque-1086 (Sigma, St. Louis, MO, 
USA) centrifugation, 1 x 106 mononuclear cells were manually pipetted 
onto the scaffold. The seeded scaffold was incubated in Dulbecco’s modified 
Eagle’s medium (Life Technologies, North Andover, MA, USA) overnight 
before implantation as described previously (35). 
 
o TEVG Implantation 
 
TEVG implantations were performed using a microsurgical technique. The 
scaffolds were inserted into the infrarenal IVC of 6- to 8- wk-old female 
mice (Jackson Laboratories as previously described (35,36). All animal 
experiments were done in accordance with institutional guidelines for the 
	  	   14	  
use and care of animals, and the Institutional Review Board at Yale 
University approved the experimental procedures described. 
 
o Transgenic Animals 
 
Transgenic inbred C57BL/6 mice that express green fluorescent protein 
(GFP) under the control of ubiquitin-C promoter were obtained (Jackson 
Laboratories) and bred in our laboratories. All animal procedures were 
approved by the Institutional Animal Care and Committee at Yale 
University.  
 
o Fate of TEVG-seeded cells 
 
Six- to 8-wk-old (20-25 g) C57BL/6 mice underwent implantation of IVC 
interposition grafts using a previously approved protocol, seeded with 1 x 
106 GFP+ BMMCs. Mice were killed postoperatively at 6 h (n = 4), 1 d (n = 
4), 3 d (n = 4), 7 d (n = 4), and 14 d (n = 4). The grafts were explanted at 
predetermined time points to assess for the fate of seeded cells using 
quantitative realtime PCR (qRT-PCR) as described previously. Explanted 
grafts were placed in lysis buffer (Qiagen). DNA extraction and 
quantification was carried out as described above. 
 
o Cell Quantification Assay 
 
The cellularity of each GFP+ BMMC-seeded scaffold was determined by 
measuring DNA content with the PicoGreen detection assay (Molecular 
Probes, Eugene, OR, USA). At 6 h and 1, 3, and 7 d of incubation, seeded 
	  	   15	  
scaffold sections were rinsed 3 times in 1 ml PBS, placed in 200 µL of 
distilled water, and stored at -80°C. At the time of evaluation, scaffold 
sections were thawed at 37°C. A black 96-well plate was loaded with 50 µL 
from each sample. A 30 µL aliquot of PicoGreen dye was mixed thoroughly 
with 6 ml of Tris-EDTA buffer (pH 7.5), and 50 µL was added to each 
sample in the 96-well plate. All samples were performed in triplicate. The 
plate was incubated in the dark at room temperature for 10 min. 
Fluorescence was measured at 188 nm excitation and 525 nm emission. 
The number of cells maintained on each scaffold was determined from a 
standard curve generated from a known quantity of mouse BMMCs. A 
negative control of unseeded scaffold sections was used for comparison 
(28,37,38). 
 
o Cell viability assay 
 
To determine GFP+ BMMC viability following seeding onto scaffold sections 
and incubation at 6 h and 1, 3, and 7 d, a CellTiter 96 AQueous 
nonradioactive cell proliferation assay (Promega BioSciences, San Luis 
Obispo, CA, USA) was performed. After seeding, all scaffold sections were 
incubated in 2 ml of RPMI 1640 (1% penicillin/streptomycin and 10% fetal 
bovine serum) for the respective incubation times. Medium was changed 
every 2 d. Following incubation, the scaffold sections were washed 3 times 
with 1 ml PBS and the assay reagent, tetrazolium compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salts (MTS), and an electron coupling reagent, 
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phenazine methosulfate, was added to each scaffold section in a 1:4 ration 
with medium and allowed to incubate for 4 h at 37°C. After 4 h, a 100 µL 
aliquot of each sample was added to a clear 96-well plate, and the 
absorbance at 490 nm was read. The relative cell viability was determined 
by the ratio of absorbance from the seeded scaffold sections incubated at 
different time points.  
 
o Bone Marrow Transplantation 
 
After myeloablation with 900 cGy total body irradiation using a 137Cs 
source, 6-wk-old female wild-type C57BL/6 mice received a tail vein 
injection of 5 x 106 unfractionated nucleated bone marrow cells (BMCs 
harvested from age-matched, sex-mismatched (male) GFP+ transgenic 
mice, as described previously (39). We confirmed engraftment of the bone 
marrow 1 mo after bone marrow transplantation by determining the 
percentage of GFP+ cells on peripheral blood using FACS. Subsequently, 
TEVGs (n = 57) were implanted as IVC interposition grafts. Specimens for 
immunostaining (n = 27) were explanted at postoperative d 3 (n = 6), 7 (n 
= 6), and 14 (n = 5), wk 10 (n = 5), and mo 6 (n = 5), and specimens for 
qRT-PCR (n =30) were explanted at postoperative d 3 (n = 6), 7 (n = 6), and 
14 (n = 6), wk 10 (n = 6), and mo 6 (n = 6).  
 
o Composite Graft Construction 
 
The vena cava was harvested from a male mouse. Sections of the vena cava 
(1mm) were anastomosed to the distal end of a scaffold. The composite 
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scaffold was then seeded and incubated as described above. The composite 
TEVG was implanted in a female host (n = 8). Specimens were harvested at 
postoperative d 7 (n = 2) and 14 (n = 2), wk 10 (n = 2), and mo 6 (n = 2).  
 
 
o Histology 
 
Explanted grafts were pressure fixed in 10% formalin overnight and then 
embedded in paraffin or glycolmethacrylate using previously published 
methods (35,36). Sections were stained with hematoxylin and eosin.  
o Immunohistochemistry 
 
Primary antibodies included rat-anti-mouse Mac-3 (BD Bioscience, San 
Jose, CA, USA), F4/80 (AbD Serotec, Raleigh, NC, USA), mouse-anti-human 
von Willebrand Factor (vWF; Dako), rabbit-anti-mouse to c-kit (Abcam), 
mouse-anti-mouse to Sox-2 (R&D Systems). Antibody binding was detected 
using appropriate biotinylated secondary antibodies, followed by binding of 
streptavidin-HRP and color development with 3,3-diaminobenzidine 
(Vector, Burlingame, CA, USA). Nuclei were then counterstained with 
hematoxylin. For immunofluorescence detection, a goat=anti-rabbit IgG-
Alexa Fluor 568 (Invitrogen, Carlsbad, CA, USA) or a goat-anti-mouse IgG-
Alexa Fluor 488 (Invitrogen) was used with subsequent 4’,6-diamidino-2-
phenylindole nuclear counterstaining.  
 
o Fluorescent in situ hybridization (FISH) 
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FISH was performed on paraffin sections using digoxigenin-labeled mouse 
Y chromosome probe detected using a rhodamine-conjugated antibody to 
digoxigenin (Roche Diagnostics, Mannheim Germany) as described 
previously (15, 16). Counting of Y+ nuclei was accomplished by 
systematically examining the FISH-stained tissue, field by field, at x 40, 
using a Zeiss Axiovert 200M Fluorescence/Live cell Imaging Microscope 
(Carl Zeiss Imaging Solutions, Thornwood, NY, USA). Digital images were 
acquired using the Zeiss LSM510 confocal computer system (Carl Zeiss 
Imaging Solutions). Images were pseudocolored using image processing 
software (Adobe Photoshop, San Jose, CA, USA). Cell counts were obtained 
by first counting all of the Y chromosome-positive (YChr+) cells in a defined 
area on the tissue and then counting the total number of cells in that area 
using the immunostained photographs.  
 
Results:  
 
qRT-PCR is a sensitive and specific method for the quantification of 
mouse DNA 
 
The initial SYBR Green qRT-PCR experiments revealed that the sensitivity 
of the GFP primers was approximately 10 genomes. GFP negative mouse 
DNA was used in this experiment as a negative control and revealed no 
amplification. To ensure that detected amplification was specific for the 
desired region of the GFP gene a melting curve on the PCR products was 
performed at the conclusion of the 40th PCR cycle. This revealed a 
consistent melting curve at 86°C at all DNA concentrations supporting that 
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amplification was specific (data not shown). To further investigate the 
specificity of the qRT-PCR reaction the PCR products were run on a 4% 
agarose gel to allow adequate resolution of small amplicons. A single 
amplification product was visualized at 98 bp which corresponded with the 
expected amplicon size based on the GFP sequence and primer pair used 
(data not shown). TaqMan qRT-PCR experiments revealed similar reaction 
sensitivities of 10 genomes. Primer concentrations of 1000 nM 
consistently resulted in increased sensitivity and thus all subsequent 
reactions contained a final concentration of 1000 nM for both the forward 
and reverse primer. The addition of 1 x 105 mouse genomes to each qRT-
PCR reaction revealed no decrease in sensitivity or specificity when 
compared to reactions carried out without the additional mouse DNA. 
  
TEVGs form neovessels resembling native veins 
 
Syngeneic BMMCs seeded onto miniaturized PGA-P(CL/LA) scaffolds were 
subsequently implanted onto the IVC of CB57BL/6 mice. Histologic 
examination of explanted grafts at 6 months revealed the presence of a 
mature laminated structure that consisted of an endothelialized intimal 
layer along with a smooth muscle layer consistent with native vein tissue 
(Fig. 1B). Scaffold material was found to be completely degraded by 6 
months. Additionally, three-dimensional computed tomography 
angiography of TEVGs at 6 months revealed no evidence of stenosis, 
aneurismal dilation, or thrombosis (Fig. 1A). 
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Fate of TEVG-seeded cells  
 
qRT-PCR performed for the GFP gene present in BMMCs seeded onto the 
TEVG in vitro demonstrated that the greatest amount of GFP DNA was 
maximal at 6 hrs following overnight incubation (Fig. 2A). The GFP DNA 
present on the scaffold decreased after 1 day of incubation.  These in vitro 
data suggest that seeded cells decrease in number during the initial 
incubation process. This is most likely secondary to a failure for the cells to 
adequately adhere to the scaffolding material and thus are washed off with 
medium changes. Cell viability and metabolic activity of the seeded BMMCs 
were both demonstrated to increase over a 7 day incubation period (Fig. 
2B). This supports the notion that the loss of cells demonstrated over the 
course of incubation is due to the cells failure to adhere to the scaffolding 
material and not due to BMMC cell death in vitro.  
 
Following 7 days of incubation TEVGs (n=30)  that had been seeded with 
GFP-labeled syngeneic BMMCs were implanted onto the IVC of 6- to 8-
week-old C57Bl/6 mice.  The TEVGs were harvested at 6 hour, and 1, 3, 7, 
and 14 days. At each time point the percentage of GFP DNA was quantified. 
We found that the seeded GFP-labeled syngeneic BMMCs disappeared with 
the increase in host-derived macrophages on the scaffold. Graft 
immunofluorescence revealed the presence of GFP-labeled cells at 6 hours 
and 1 and 3 days. However, at 7 days post implantation no GFP cells were 
identified on the scaffold (Fig. 2C).  These data were further supported by 
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qRT-PCR for GFP DNA on explanted TEVGs. Over the course of 14 days 
following graft implantation the GFP concentration on the graft was shown 
to decrease rapidly from a high of 173 genomes/µL at 6 hours post-
implantation to 0.12 genomes/µL at 14 days post-implantation. The 
percentage of GFP+ cells per TEVG was found to decrease from 4.37% at 6 
hours to 0.02% at 14 days (Fig. 2E).  In an effort to demonstrate that this 
decrease in cell percentages was due to the loss of GFP+ cells, and not 
simply a result of a dilutional effect caused by the influx of host cells the 
data were standardized. This standardization further recapitulated that 
initial GFP+ cells were indeed lost following implantation of the graft.  
 
BMCs are not the ultimate source of vascular neotissue 
 
Building on the aforementioned results a series of experiments were 
designed in an effort to identify the source of the cells that ultimately come 
to populate the implanted scaffold. The role of host BMCs in neotissue 
formation was investigated by creating chimeras of rescued lethally 
irradiated C57BL/6 female mice with sex-mismatched male GFP+ total 
BMCs from transgenic GFP-labeled mice. Donor cell engraftment within the 
surviving recipients was determined at 5 weeks following bone marrow 
transplantation and FACS analysis of peripheral blood GFP-labeled mice 
demonstrated 97.74% circulating GFP+ cells in a positive control mouse 
(Fig. 3A), 0.49% in a negative control mouse (Fig. 3B), and 94.06% 
reconstitution in transplanted mice (Fig. 3C).  TEVGs were implanted in 
female mice following successful creation of the chimeras. Following graft 
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implantation the mice were killed at 3, 7, and 14 days, 10 weeks, and 6 
months. Grafts were evaluated histologically and YChr+ cells were 
demonstrated in the graft wall at 3 and 7 days following implantation. 
These cells were primarily male-derived macrophages as determined by 
colocalization of YChr+ and F4/80 antibody cells.  These YChr+ BMCs 
continued to increase in number and at day 14 days both endothelial cells 
and smooth muscle cells began to appear. The cells comprising the 
developing neotissue were positive for vWF and SMA and negative for 
YChr (Fig. 4D, E). A confluent neointima comprised of endothelial cells and 
neomedia comprised of smooth muscle cells were present by week 10. 
These layers were both negative for YChr+ cells. Finally, the last time point 
at 6 months post-implantation revealed a smooth muscle layer composed 
of calponin+ YChr- cells with a endothelial  layer of vWF+ YChr- cells (Fig. 
4A, B). The original scaffold material was nearly completely degraded with 
the presence of scant inflammatory cells positive for MAC-3 and YChr (Fig. 
5B). The infiltration of BM-derived YChr+ cells in the implanted graft wall 
increased during the initial 10 weeks following implantation, however by 
the 6 month time point the presence of these cells was greatly decreased 
(Fig. 4C). These observations provided by immunohistochemistry were 
further recapitulated quantitatively by using qRT-PCR for GFP DNA within 
the graft over an identical time course (Fig. 4D). These data revealed that 
following graft implantation the initial scaffold infiltrates were 
macrophages originating in the bone marrow. Following this initial 
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inflammatory infiltrate the presence of endothelial and smooth muscle 
cells lacking colocalization of cell markers specific to each tissue type with 
the Y chromosome were present with a decreasing presence of 
inflammatory cells (Fig. 4E).  
 
Neovessel formation arises from ingrowth of vascular cells from the 
neighboring blood vessel 
 
While the bone marrow appears responsible for an initial inflammatory 
infiltrate following graft implantation, the source of the endothelial and 
smooth muscle cells was demonstrated in previous experiments to be 
derived of cells not of bone-marrow-origin. An experiment was designed to 
investigate the possibility that the graft neotissue’s origins lay in the cells 
of the blood vessel adjacent to the implanted graft. A composite vascular 
graft was created by anastomosing a segment of syngeneic male IVC with a 
TEVG scaffold (Fig. 5A). The entire composite vascular graft (n=8) was 
implanted into a female host. The grafts were harvested at 7 and 14 days, 
10 weeks, and 6 months post-implantation. After paraffin embedding all 
grafts were cut longitudinally so that male IVC (donor), TEVG, and female 
(host) IVC were included. FISH specific to Y chromosome was performed 
on the explanted grafts. At days 7 and 14 following graft implantation the 
majority of the graft were populated by MAC 3+/YChr- cells (host origin). 
At these time points no confluent endothelial or smooth muscle cell layers 
were identified.  However, at day 14 a non-confluent endothelial and 
smooth muscle layer positive for vWF and calponin respectively were 
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noted. The confluence of these cell layers was greatly increased by 10 
weeks postimplantation. At 6 months postimplantation the neovessel was 
composed of a confluent neointima, neomedia and a neoadventitia. Using 
FISH it was revealed that cells comprising the neotissue adjacent to the 
male IVC (donor) contained the highest percentage of YChr+ cells (Fig. 5B, 
C). The neotissue adjacent to the female (host) IVC lacked YChr+ cells. 
These, along with the previously discussed findings, suggest that the cells 
that ultimately come to permanently populate the graft and create the 
viable neovessel have their origins in the vessel adjacent to the implanted 
scaffold. This is contrary to previous proposed mechanisms that 
hypothesized that the source of cells ultimately creating the neovessel 
were derived from the seeded cells or from bone marrow progenitor cells. 
Instead it suggests a mechanism involving a locally mediated process of in 
growth of endothelial and smooth muscle cells from the surrounding native 
vessel.  
 
Discussion: 
 
As the clinical trial performed by Shinoka has shown that the use of TEVGs 
in the repair of single ventricle is both effective and safe with results that 
clearly represent an improvement over the standard of care (29). As 
previously stated, despite the efficacy and excellent safety profile of TEVGs 
in these repairs, stenosis has continued to plague grafts requiring 
subsequent stenting or angioplasty to correct. With this knowledge we 
returned to the laboratory in an effort to elucidate the mediators of 
	  	   25	  
stenosis in implanted TEVGs. This study’s purpose was specifically to 
determine the source of the cells that ultimately create the neotissue in 
implanted TEVGs. In effort to make this determination, the origins of 
vascular neotissue cells in a syngeneic immunocompetent mouse recipient 
using bone marrow chimeric hosts and composite vascular implants was 
investigated. To mimic the high-flow, low-pressure venous setting that one 
would encounter in clinical applications related to the repair of congenital 
heart defects the PGA-P(CL/LA) tubular scaffolds were miniaturized  and 
seeded with syngeneic BMMCs prior to implantation into the mouse IVC.  
 Previous work published by the laboratory was validated in the 
observation that the seeded cells from the TEVG following implantation 
disappeared precipitously. These data were of increased clinical relevance 
in this study in that an immune-competent murine model was used. 
Additionally, to track the fate of the seeded BMMCs used in this study, 
TEVGs that were implanted were constructed by seeding the scaffolds with 
GFP-labeled syngeneic BMMCs. These scaffolds were harvested over a time 
course of 2 weeks. At each time point the percentage of GFP-positive DNA 
was quantified by using RT-PCR. Findings were consistent to a previous 
study using a human into mouse xenogeneic model in that the seeded cells 
disappeared after implantation as the scaffold became populated by host-
derived cells. These cells that initially populate the implanted scaffold were 
identified as F4/80-expression macrophages. While this decrease in the 
percentage of GFP-positive cells present on the TEVGs could have been 
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simple secondary to a dilutional effect due to the increased cell density 
caused by infiltrating macrophages, this possibility was ruled out by 
standardizing the data to reflect cell density.  It was again observed, as has 
been described in previous studies, that over the course of 6 months 
following implantation the scaffold material completely degrades and the 
TEVGs display a vascular architecture similar to that of native vein.  
 The results of the previous experiments clearly show that contrary 
to the traditional hypothesis, the cells seeded onto the TEVG prior to 
implantation do not differentiate, divide and subsequently becoming the 
vascular neotissue observed at 6 months. Instead the source of the cells 
that ultimately comprise the vascular neotissue must have an alternate 
source. The two hypotheses that we proposed regarding the source of these 
cells were the host’s bone marrow-derived cells or the cells comprising the 
adjacent vasculature itself.  In an effort to address the possibility that the 
source of the cells were the host’s bone marrow-derived cells, TEVGs were 
implanted into female mice that had undergone bone marrow 
transplantations with syngeneic male bone marrow. These TEVGs were 
harvested at numerous time points over the course of 6 months. Harvested 
grafts were analyzed using FISH for the Y chromosome. A number of other 
cellular markers were included as well such as F4/80 for macrophages, 
calponin for smooth muscle cells, and vWF for endothelial cells. These 
experiments revealed that the macrophages seen immediately infiltrating 
the TEVG following graft were positive for Y chromosome indicating that 
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they are derived from the bone marrow. However, at later time points after 
the development of vascular neotissue, there was no evidence of 
colocalization of either smooth muscle cell markers or endothelial cell 
markers with the marker for the Y chromosome. These data suggest that 
while the initial host response to the implanted TEVG in the form of 
infiltrating macrophages is derived from the host’s bone marrow, the cells 
that ultimately become the neotissue are from an alternate source. 
 The second proposed hypothesis that we investigated was that the 
source of the cells that ultimately comprise the vascular neotissue is the 
neighboring blood vessel itself. A composite vascular graft created by 
anastomosing a segment of syngeneic male IVC proximally to the TEVG. 
The entire TEVG with the anastomosed male IVC was implanted into a 
female host. As in previous experiments these were harvested over a 6 
month time period. The explanted grafts were analyzed using FISH to 
identify Y chromosome presence along with the presence of endothelial 
and smooth muscle cells. Contrary to previous experiments both 
endothelial cells and smooth muscle cells were found to contain the Y 
chromosome. Additionally, the percentage of cells that were positive for 
the Y chromosome was noted to be greatest adjacent to the implanted male 
IVC segment. As one moves distally along the implanted TEVG a decline in 
cells positive for the Y chromosome was noted.  These data suggest that the 
source of cells ultimately comprising the neotissue arise from the in 
growth of cells from the adjacent blood vessel segments both proximally 
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and distally to the implanted TEVG. It is likely these cells are already fully 
differentiated prior to ingrowth, however our experiments cannot rule out 
the possibility that there exists a rare population of stem cells that reside 
within the adjacent vascular segments. In an effort to investigate this 
possibility immunohistochemistry staining was performed for both stem 
cells and progenitors. This staining provided no evidence for the presence 
of non-differentiated cells further suggesting that the source of the cells is 
fully differentiated neighboring endothelial and smooth muscle cells.  
Our study has allowed for a significantly increased understanding of 
the process of TEVG formation following implantation. The most valuable 
information that our study provides to the understanding of the 
development of TEVGs is that in our mouse model the cells that become the 
intima and media of the neovessel are derived from the vessel wall of 
proximal and distal neighboring vasculature.  The finding that cells seeded 
onto the biodegradable scaffold prior to implantation are not directly 
responsible for the growth of cells on the scaffold represents a paradigm 
shift with respect to the previous hypothesis.  
The next step is to use these discoveries in the creation of a second-
generation TEVG with the goal of significantly decreasing the graft stenosis 
rate. While grafts have been shown to remain patent following 
implantation without cell-seeding, the rate of stenosis and subsequent graft 
failure is much greater in these non-seeded TEVGs. Although our data 
suggest the role of seeded cells is secondary to the ultimate formation of 
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TEVG neotissue it is possible that they help facilitate an accelerated host 
response and thus expedited formation of the neovessel. This acceleration 
could alone account for the decrease in stenosis and graft failure due to a 
decrease in the amount of time that the host’s pro-coagulant blood 
products are exposed to the scaffold material and the possible turbulent 
flow that may result. Future experiments should be focused on identifying 
critical molecular mediators of stenosis. Once these have been identified, 
grafts could be designed with improved long-tem patency. Secondly, the 
molecular mechanisms controlling vascular neotissue formation should be 
elucidated. Because our experiments have demonstrated that seeded cells 
are not directly responsible for graft population, it can be deduced that the 
role that the seeded cells is of paracrine nature. By identifying mediators 
of this paracrine response it would be possible to create grafts that elute 
cytokines, thus obviating the need for cell-seeding.  
Preliminary studies have supported this hypothesis finding that 
seeded grafts recruit significantly more macrophages suggesting that this 
recruitment is of importance in the formation of patent neovessels. 
Additionally, MCP-1 along with IL-1β were detected in abundance in seeded 
grafts. Subsequent studies in which scaffolds containing alginate 
microspheres were implanted into mice revealed that the controlled 
release of MCP-1 allowed by the alginate microspheres prevented graft 
stenosis in the absence of cell seeding. These results suggest that the MCP-
1 released following implantation recruit host monocytes to the graft 
	  	   30	  
which participate in the formation of vascular neotissue by means of an 
inflammation-mediated process of vascular remodeling (40). Further 
studies further characterizing this process will help to further elucidate 
the molecular players involved with the aim of creating improved TEVGs 
in the future.  
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Figure 1. A) CT angiogram of a TEVG IVC interposition graft 6 mo after 
implantation. TEVG is colored blue. B) Representative photomicrographs 
of immunohistochemical characterization of the native IVC compared with 
the TEVG 6 mo after implantation (hematoxylin and eosin, x100; CD31 
and Cal, x400). 
 
 
 
 
 
 
 
	  	   34	  
 
 
 
 
 
 
 
 
 
Figure 2. A) DNA assay of scaffolds from 0 h to 7 d of in vitro incubation 
showed increased number of cells in first 24 h and loss of cells after 72 h. 
B) MTS assay of scaffolds from 0 h to 7 d in vitro incubation showed initial 
increase in metabolic activity followed by steady state. C) In vivo tracking 
using immunofluorescence (x630) demonstrated GFP+ cells within the 
graft at 6 h and 1 and 3 d but no cells at 7 d postimplantation. D) These 
findings were corroborated by qRT-PCR for the GFP gene from TEVGs 
(n=30) seeded with GFP+ cells, implanted in GFP-negative hosts, and 
harvested between 6 h and 14 d after implantation. Level of detection is 10 
genomes/µl. E) Percentage of GFP-labeled cells per TEVG standardized for 
cell density decreased form 4.37% at 6 h to 0.02% at 14 d. Data are 
expressed as means ± SD. 
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Figure 3. A-C) FACS analysis of GFP+ mouse as positive control (A), 
C57BL/6 mouse for negative control (B), and engraftment 5 wk post-
transplantation (C). D) Schematic demonstrating components and 
orientation of photomicrographs. E, F) Confocal microscopic images of 
TEVG implanted into female host that had undergone transplantation with 
male bone marrow harvested 14 d after implantation, demonstrating no 
colocalization with the Y chromosome (Y-chromosome FISH and either 
endothelial cells (EC; vWF, x630; E) or smooth muscle cells (SMC; 
calponin, x630; F). 
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Figure 4. A)Schematic demonstrating components and orientation of 
photomicrographs. B) Confocal microscopic images of TEVG implanted into 
female host that had undergone transplantation with male bone marrow 
harvested 6 mo after implantation, demonstrating colocalization of 
macrophages (MAC) and the Y-chromosome (Y-chromosome FISH) but no 
colocalization with the Y chromosome (Y-chromosome FISH) and either 
endothelial cells (vWF) or smooth muscle cells (Calponin; x400). C) 
Numbers of infiltrating BM-derived Y chromosome (Y-chromosome FISH) 
cells (bone marrow cells/high power field) in the graft wall increased up to 
10 wk, while graft degradation was occurring, but at 6 mo 
postimplantation, these cells markedly decreased. D) This was quantified 
and corroborated using qRT-PCR for GFP DNA within the graft over a 6 mo 
period. E) Confocal microscopic image of triple staining of a 6 mo neovessel 
with normal IVC configuration with single-layer neointima (EC;vWF/light 
blue), neomedia (SMC; calponin/green), and neoadventitia with scattered 
inflammatory cells (male;Ychr/red). 
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Figure 5. Schematic demonstrating composite TEVG (n=8) created by 
anastomosis of a syngeneic male IVC with a TEVG, implanted into a female 
host and harvested at 6 mo after implantation, and the percentage of cells 
with Y-chromosome as a function of distance from the male IVC. A) 
Confocal microscopic images demonstrating colocalization of endothelial 
cells (VWF) and Y chromosome (Y chromosome FISH;x400). C) 
Photomicrographs demonstrating colocalization of smooth muscle cells 
(calponin) and Y chromosome (Y-chromosome FISH; x400).  
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